NOVALIQ COMPLETES ENROLLMENT OF SECOND PHASE 3 STUDY FOR CYCLASOL® FOR THE TREATMENT OF DRY EYE DISEASE
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the second of two Phase 3 (ESSENCE-2) studies, evaluating the investigational drug CyclASol® to treat the signs and symptoms of dry eye disease DED, has been completely enrolled with a total of 834 participants.